Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 4 1Phase 2 1

Status

Completed 2

Sponsor Class

OTHER 8INDUSTRY 2OTHER_GOV 1

Study Type

Interventional 2

Sponsor

Cancer Type

Classical hematology 2

Conditions

Venous Thromboembolism 2Abdominal Neoplasms 1

Interventions

Carboplatin 315Paclitaxel 303Cisplatin 250Docetaxel 238pembrolizumab 230Gemcitabine 214Pemetrexed 158Capecitabine 147Rituximab 144Bevacizumab 142Dexamethasone 125Fluorouracil 121Cyclophosphamide 102Trastuzumab 100Doxorubicin 96Nivolumab 93Prednisone 92Oxaliplatin 90atezolizumab 75Leucovorin 72durvalumab 69130-nm albumin-bound paclitaxel 68Injections 66Lenalidomide 63Irinotecan 62Bortezomib 56Letrozole 54Topotecan 53Fulvestrant 53Drug Therapy 50

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × INDUSTRY × Enoxaparin × Clear all
NCT01583218 2023-08-07

APEX

Alexion Pharmaceuticals, Inc.

Phase 3 Completed
7,513 enrolled 18 charts 1 FDA
Classical hematology

Venous Thromboembolism

NCT00723216 2010-04-05

Japanese Efficacy and Safety Study of Enoxaparin in Patients With Curative Abdominal Cancer Surgery

Sanofi

Phase 3 Completed
151 enrolled
Classical hematology

Abdominal Neoplasms, Venous Thromboembolism

Data powered by HemOnc (CC BY 4.0) Colophon âš¡